menu search

FNCH / Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why

Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why
Finch Therapeutics Group, Inc. (FNCH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Read More
Posted: Sep 5 2022, 13:33
Author Name: Zacks Investment Research
Views: 102053

FNCH News  

4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650%

By PennyStocks
April 19, 2023

4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650%

Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650% appeared first on Penny Stocks t more_horizontal

Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates

By Zacks Investment Research
November 10, 2022

Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates

Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 20 more_horizontal

Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why

By Zacks Investment Research
September 5, 2022

Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why

Finch Therapeutics Group, Inc. (FNCH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. more_horizontal

Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022

By GlobeNewsWire
May 9, 2022

Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022

SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinica more_horizontal


Search within

Pages Search Results: